固酶-5抑制剂和痴呆症风险:在现实世界研究中根据指示进行混
Che-Yuan Wu1,2, Walter Swardfager1,2
1Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.
Journal of Alzheimer's disease : JAD
|July 12, 2024
概括
西尔德纳菲尔可能会降低痴呆症风险,但根据指示的混需要在药物流行病学研究中仔细选择对比剂. 需要进一步的研究来证实这些发现,并了解潜在的药物用于痴呆症的重新用途.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 流行病学 流行病学
背景情况:
- 常规收集的数据有助于药物重定向用于痴呆症预防和治疗.
- 最近的一项研究表明,与心血管药物相比,使用西尔代纳菲尔与痴呆症风险降低54%有关.
研究的目的:
- 突出在药物流行病学研究中选择适当的活性比较剂的关键重要性.
- 评估在研究中将固酶-5抑制剂与降低痴呆风险联系起来时,因适应症而存在混风险.
主要方法:
- 对药物流行病学研究方法的审查.
- 在药物重定位研究中,根据指示对混的分析.
- 在观察性研究中强调对比者选择.
主要成果:
- 药物流行病学研究可以确定潜在的药物重定向候选人痴呆症.
- 根据适用情况进行混在与不同适用情况的药物进行比较时构成重大挑战.
- 不恰当的比较者选择可能导致关于痴呆风险的偏见结果.
结论:
- 在药物流行病学研究中,仔细选择活性比较剂至关重要,以避免偏见.
- 固酶-5抑制剂与较低的痴呆风险之间的潜在联系需要通过强大的方法进一步调查.
- 对于可靠的药物重定向研究来说,了解和减轻因指示而引起的混至关重要.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
144
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
144
Alzheimer's Disease: Treatment
177
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
177
Dementia
110
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
110
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
118
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
118
Parkinson's Disease: Treatment
251
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
251
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
119
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
119


